Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Simon Barry J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:159,146Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Simon Barry J.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:45,731Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Lauer Regan JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:42,439Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Lauer Regan JOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,195Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Sachs David C.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:424,390Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Sachs David C.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:121,951Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Adcock RichardOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,591,463Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Adcock RichardOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:457,317Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Soon-Shiong PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,193,597Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Soon-Shiong PatrickOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:342,987Price:--
Filings by filing date
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Simon Barry J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:159,146Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Simon Barry J.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:45,731Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Lauer Regan JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:42,439Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Lauer Regan JOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,195Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Sachs David C.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:424,390Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Sachs David C.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:121,951Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Adcock RichardOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,591,463Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Adcock RichardOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:457,317Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Soon-Shiong PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,193,597Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Soon-Shiong PatrickOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:342,987Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://immunitybio.com |
IR: | See website |
Key People | ||
Patrick Soon-Shiong Executive Chairman of the Board, Global Chief Scientific and Medical Officer | Richard Adcock President, Chief Executive Officer, Director | David Sachs Chief Financial Officer |
Lennie Sender Chief Operating Officer | Enrique Dilone Chief Technology Officer | Barry J. Simon Chief Corporate Affairs, Director |
Business Overview |
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. |
Financial Overview |
For the fiscal year ended 31 December 2023, Immunitybio Inc revenues increased from $240K to $622K. Net loss increased 40% to $583.2M. Revenues reflect Europe segment increase from $198K to $591K. Higher net loss reflects Interest expense - Balancing value increase from $63.4M to $129.1M (expense), Change in fair value of warrant liabilit decrease from $13.5M (income) to $47.6M (expense). |
Employees: | 628 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,881M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.62M as of Dec 31, 2023 |
EBITDA (TTM): | -$341.76M as of Dec 31, 2023 |
Net annual income (TTM): | -$583.20M as of Dec 31, 2023 |
Free cash flow (TTM): | -$397.34M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $571.97M as of Dec 31, 2023 |
Shares outstanding: | 673,952,278 as of Mar 14, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |